Nilai Prognostik FLT3 Pada Pasien Leukemia Mieloid Akut

Hendra Asputra

Abstract

Acute myeloid leukemia (AML) is a disease characterized by neoplastic transformation and abnormality of progenitor cells differentiation from myeloid cells. In AML there is a heterogeneous abnormality in hematopoietic progenitor cells, this abnormality has been identified and affects the balance between proliferation, survival and differentiation of body cells. Mutation of FMS-like tyrosin kinase 3 (FLT3) gene causes overexpression which is one of the most often found mechanism that has been identified could trigger genetic changes that can disturb intracellular signaling tissue in pathogenesis of leukemia. Besides being used as a diagnostic tool, FLT3 overexpression can also be used to assess the prognosis of AML.

Keywords

FLT3, Leukemia Mieloid Akut

Full Text:

PDF

References

Wetzler M. Acute and chronic myeloid leukemia. harrisons principles of internal medicine. 16th edition. Mc graw Hill. 2005;1:631-641.

Mehta A & Hoffbrand V. Leukemia akut. Klasifikasi dan diagnosis. At a glance hematology. Airlangga. 2008;2:52-3.

Suzanna E, Sirait T, Rahayu PS, Shalmont G, Anwar E, Andalusia R, et al. Registrasi kanker berbasis rumah sakit di rumah sakit kanker dharmais. Pusat kanker nasional. Indonesian journal of cancer. 2012;6(4):181-196.

Fey MF, Greil R, Jost LM. ESMO Clinical recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Annals of oncology. 2005;16(1):40-49.

Bakta IM. Hematologi Klinik. EGC. Jakarta. 2006:121-149.

Zuo Z. Molecular dignostics of acute myeloid leukemia. Review Diagnostic Histopathology, Elsevier, USA. 2009:531-9.

Abdel WO & Zuckerman. Molecular genetics of acute myeloid leukemia: Clinical implications and opportunities for integrating genomics into clinical practice. Leukemia and human oncology, memorial sloan-kettering cancer centre, New York, USA. 2012:39-42.

Mrozek K & Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Division of hematology and oncology, departement of internal medicine, comprehensive cancer centre the ohio state university, Columbus. 2006:169-177.

Vora HH, Shukla SN, Brahambhatt BV, Mehta SV, Patel N, Parikh SK, et al. Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia. Asia pacific journal of clinical oncology, India. 2010:306-319.

Kurnianda J. Leukemia mieloid akut. Dalam Buku Ajar Ilmu Penyakit Dalam Edisi kelima, jilid II, editor Sudoyo A dkk. Interna Publishing, Jakarta. 2009:1234-1240.

Smith M, Barnett M, Bassan R, Gemma G, Tondini C and Kern W. Adult acute myeloid leukemia. Critical reviews in oncology and hematology. 2004:197-222.

Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Journal of hematology & oncology Japan.2011:1-10.

Arber DA, Carter NH, Ikle D and Slovak M. Value of combined morphologic, cytochemical, and immunophenotypic features in predicting recurrent cytogenetic abnormalities in acute myeloid leukemia. Human Pathology. 2003;35(5):1-9.

Grafone T, Palmisano M, Nicci C, Storti S. An Overview on the Role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Departement of Onco-Hematology. Italy. 2012:64-74.

Testa U & Pelosi E. The Impact of FLT3 mutations on the development of acute myeloid leukemias. Review Article. Leukemia Research and Treatment. 2013:1-14.

Kim KT, Levis M, Small D. Constitutively activated FLT3 phosphorylates BAD partially through pim1. Br J Haematol. 2006;134:500-9.

Ikeda A, Shankar DB, Watanabe M, Tamanoi F, Moore TB, Sakamoto KM. Molecular targets and the treatment of myeloid leukemia. Minireview. Division of Hematology/ Oncology Department of Pediatrics, Jonsson Comprehensive Cancer Centre, USA. 2006:216-24.

Meshinchi S & Appelbaum FR. Structural and functional alteration of FLT3 in acute myeloid leukemia. Molecular Pathways. Clin Cancer Res. 2009;15(13):4263-9.

Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Section of hematology & oncology, Departement of Medicine and the cancer research center, University of Chicago, Chicago USA. 2010:50-57.

Del Poeta, Ammatuna E, Lavorgna S, Capelli G, Zaza S, Luciano F, et al. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bx/bcl-2 ratio and favourable outcome in acute myeloid leukemia. British Journal of Haematology. Blackwell publishing. Italy. 2010:383-7.

DOI: https://doi.org/10.26891/JIK.v15i1.2021.1-7

Refbacks

  • There are currently no refbacks.